We use cookies to make this site work. We'd also like to set optional cookies so we can understand how the site is used and improve it. We will not set optional cookies unless you accept them. You can change your choice at any time from the Cookie settings link in the footer.
Strictly necessary cookies
These cookies are required for the site to work. They store your cookie preferences and keep your session secure. They are exempt from consent under PECR Regulation 6(4) because they are essential to deliver the service you have requested.
Optional cookies
Optional cookies help us understand how the site is used and provide additional features such as analytics, accessibility tools and translation. We will only set them if you accept.
Mounjaro Update
As from 23rd June 2025, following approval by NICE, tirzepatide (Mounjaro®) will be available in the NHS for eligible patients who meet the strict, nationally-set, criteria.
The current criteria is that patients are those with a BMI of 40 or higher, and with four or more of the qualifying comorbidities (hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes) will be eligible for assessment to identify their suitability for Mounjaro.
Anyone not meeting these criteria will NOT be eligible for assessment in the first year of the drug being available.
Please do not contact your GP; if you are eligible to be assessed you will be contacted over the coming months and invited to attend an appointment for assessment. Those with the greatest clinical need will be contacted first.
For full details , please visit here.
Published: Jun 25, 2025